Home > Agne Paner, ASH 2019: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias
Haematological Malignancies

Agne Paner, ASH 2019: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias

Published Online: December 18th 2019

At the 61st ASH Annual Meeting & Exposition, Agne Paner, Rush University Medical Center, discusses her presentation: Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias.

Questions

1. What are the major unmet needs in the treatment of relapsed/refractory multiple myeloma? (0:05)

2. What were the findings of the HORIZON study? (0:28)

3. What progress has been made in identifying biomarkers of response to Melflufen plus Dexamethasone in relapsed/refractory multiple myeloma? (1:37)

4. What combination therapies are being investigated for relapsed/refractory multiple myeloma? (1:53)

5. How does this treatment differ from other treatment options? (2:42)

 

Agne Paner has received consulting honoraria for advisory board from Oncopeptides.

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

Share this Video
Related Videos In Haematological Malignancies
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar